genetic familial mutations
492 articles
Progress in BRCA-Related Cancers Highlighted By the Basser Center
The Basser Center for BRCA hosted a panel discussion of the latest breakthroughs and discoveries for BRCA-related cancers.
Genetic Testing for All Pancreatic Cancer Patients
A study by Dr. Gloria Petersen’s research team has led to an official recommendation that all pancreatic cancer patients get genetic testing.
Focusing on a Drug that Treats Specific Tumor Mutations
A clinical trial tests a signal-inhibiting drug for lung cancers with specific genetic mutations on gastrointestinal cancers with the same tumor mutations.
This Versus That: Words to Know
Confused about some of the similar-sounding terms you are hearing during pancreatic cancer treatment? Our list of words to know can help.
PARP Inhibitors for Pancreatic Cancer Maintenance Treatment
Dr. Kim Reiss Binder is leading a clinical trial of maintenance treatment with the PARP inhibitor rucaparib, for patients who carry the BRCA mutation.
Genetic Testing Can Help Those You Love
Dr. Fay Kastrinos, director of the Muzzi Mirza Pancreatic Cancer Prevention and Genetics Program at Columbia University Medical Center, explains the value of genetic testing for cancer prevention and treatment.
A Potential Role for PARP Inhibitors in Pancreatic Cancer
Dr. Michael Pishvaian leads research into the possible role of PARP inhibitors in treating pancreatic cancer patients with certain genetic mutations.
BRCA’s Role in Pancreatic Cancer Investigated
The relationship between BRCA and pancreatic cancer, and how that affects treatment, is the focus of clinical trials looking at PARP inhibitors.
Using Tumor Tissue Samples to Break Down Assumptions About Pancreatic Cancer
Dr. Christine Iacobuzio-Donahue uses tumor tissue samples to study how pancreatic cancer tumors develop, so she can find ways to stop the disease.
PRECEDE Trial Sets Survival Rate Goal
Dr. Raymond Wadlow explains how earlier detection of high-risk people is key the PRECEDE trial’s goal to increase pancreatic cancer survival rates.
A Maintenance Trial for Patients with BRCA or PALB2 Mutations
A clinical trial examines whether the PARP inhibitor rucaparib can work as a maintenance drug for pancreatic cancer patients with BRCA or PALB2 mutations.
Pancreatic Cancer: 2018 Highlights And Looking Forward to 2019
Dr. Allyson Ocean leads an overview of the new treatments and protocol from 2018 as well as what are the next steps in treatment for 2019.
Genetic Testing Guided My Treatment Plan
Ryan Dwars already knew there was pancreatic cancer in his family so when he was diagnosed he asked for genetic testing right away.
Most Cancer Mutations Are Random DNA Mistakes
In a large study, Dr. Bert Vogelstein of Johns Hopkins found that a majority of cancers, including pancreatic cancer, are caused by random mutations of DNA.